Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Dublin-based generics company Actavis buys US spec pharma Forest Laboratories for $23.9bn

Executive Summary

Dublin-based global generics company Actavis PLC acquired US specialty pharma Forest Laboratories Inc. in a cash and stock deal worth $23.9bn. Forest stockholders get $88.04 per share ($26.04 cash and 0.3306 Actavis shares (worth $62 based on the ten-day average)), a 29% premium.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Pulmonary
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Payment Includes Stock
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register